Literature DB >> 7547224

The genetics of breast and ovarian cancer.

D Ford1, D F Easton.   

Abstract

A number of genes are known to be involved in inherited susceptibility to breast and/or ovarian cancer. In the context of high-risk families the most important genes are BRCA1 on chromosome 17q, which is associated with a high penetrance of both breast and ovarian cancer, and BRCA2 on chromosome 13q, which causes a high risk of breast cancer but a lower risk of ovarian cancer. Other high-risk cancer genes that confer increased risks of breast or ovarian cancer in addition to other cancers include the hereditary non-polyposis colorectal cancer genes and the TP53 gene, which causes breast cancer as part of the Li-Fraumeni syndrome. The predisposing mutations in these genes are relatively rare in the population. More common genes which are associated with an increased, but lower, risk of breast cancer are the ataxiatelangiectasia gene and the HRAS1 gene. This paper reviews recent progress in mapping and cloning of these susceptibility genes, and provides estimates of the cancer risks associated with each gene and the frequency of predisposing mutations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547224      PMCID: PMC2034018          DOI: 10.1038/bjc.1995.417

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  53 in total

1.  Genetic steps in colorectal cancer.

Authors:  W Bodmer; T Bishop; P Karran
Journal:  Nat Genet       Date:  1994-03       Impact factor: 38.330

2.  Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer.

Authors:  K W Jolly; D Malkin; E C Douglass; T F Brown; A E Sinclair; A T Look
Journal:  Oncogene       Date:  1994-01       Impact factor: 9.867

3.  A novel approach to estimate the proportion of hereditary nonpolyposis colorectal cancer of total colorectal cancer burden.

Authors:  L A Aaltonen; R Sankila; J P Mecklin; H Järvinen; E Pukkala; P Peltomäki; A de la Chapelle
Journal:  Cancer Detect Prev       Date:  1994

4.  Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.

Authors:  E Steichen-Gersdorf; H H Gallion; D Ford; C Girodet; D F Easton; R A DiCioccio; G Evans; M A Ponder; C Pye; S Mazoyer
Journal:  Am J Hum Genet       Date:  1994-11       Impact factor: 11.025

5.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.

Authors:  D E Goldgar; D F Easton; L A Cannon-Albright; M H Skolnick
Journal:  J Natl Cancer Inst       Date:  1994-11-02       Impact factor: 13.506

6.  A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis.

Authors:  D E Goldgar; P Fields; C M Lewis; T D Tran; L A Cannon-Albright; J H Ward; J Swensen; M H Skolnick
Journal:  J Natl Cancer Inst       Date:  1994-02-02       Impact factor: 13.506

Review 7.  Genetics of breast and ovarian cancer.

Authors:  S A Narod
Journal:  Br Med Bull       Date:  1994-07       Impact factor: 4.291

8.  Mutations of two PMS homologues in hereditary nonpolyposis colon cancer.

Authors:  N C Nicolaides; N Papadopoulos; B Liu; Y F Wei; K C Carter; S M Ruben; C A Rosen; W A Haseltine; R D Fleischmann; C M Fraser
Journal:  Nature       Date:  1994-09-01       Impact factor: 49.962

9.  Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.

Authors:  M R Stratton; D Ford; S Neuhasen; S Seal; R Wooster; L S Friedman; M C King; V Egilsson; P Devilee; R McManus
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

10.  Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; D T Bishop; S A Narod; D E Goldgar
Journal:  Lancet       Date:  1994-03-19       Impact factor: 79.321

View more
  39 in total

1.  The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study.

Authors:  J F Stratton; D Thompson; L Bobrow; N Dalal; M Gore; D T Bishop; I Scott; G Evans; P Daly; D F Easton; B A Ponder
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

Review 2.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

3.  High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects.

Authors:  G Goelen; E Teugels; M Bonduelle; B Neyns; J De Grève
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

4.  Screening for ovarian cancer: recommendation statement.

Authors: 
Journal:  Ann Fam Med       Date:  2004 May-Jun       Impact factor: 5.166

Review 5.  [Evaluation of cancer risk through genetic analysis?].

Authors:  A Luz
Journal:  Strahlenther Onkol       Date:  1997-09       Impact factor: 3.621

6.  Educating physician assistants as agents in cancer control: issues and opportunities.

Authors:  Quentin W Smith; Carl E Fasser; Laurel R Spence; Robert J McLaughlin; J David Holcomb
Journal:  J Cancer Educ       Date:  2007       Impact factor: 2.037

7.  Population-Calibrated Gene Characterization: Estimating Age at Onset Distributions Associated With Cancer Genes.

Authors:  Edwin S Iversen; Sining Chen
Journal:  J Am Stat Assoc       Date:  2005       Impact factor: 5.033

8.  Role of the ataxia-telangiectasia gene (ATM) in breast cancer. A-T heterozygotes seem to have an increased risk but its size is unknown.

Authors:  M Lavin
Journal:  BMJ       Date:  1998-08-22

9.  Missense mutations in disease genes: a Bayesian approach to evaluate causality.

Authors:  G M Petersen; G Parmigiani; D Thomas
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

10.  Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.

Authors:  Reshma Jagsi; Kent A Griffith; Allison W Kurian; Monica Morrow; Ann S Hamilton; John J Graff; Steven J Katz; Sarah T Hawley
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.